Image de couverture de livre

Optimal Cut‐Point Selection Methods Under Binary Classification When Subclasses Are Involved

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Jia Wang, Lili Tian
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Pharmaceutical Statistics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Methodological Approaches for the Estimation of Confidence Intervals on Partial Youden Index Under Verification Bias
par: Sihan Jia, et autres
Publié: (2026)

A Tipping Point Method to Evaluate Sensitivity to Potential Violations in Missing Data Assumptions
par: Cesar Torres, et autres
Publié: (2025)

Assessing the Operational Characteristics of the Individual Causal Association as a Metric of Surrogacy in the Binary Continuous Setting
par: Fenny Ong, et autres
Publié: (2024)

PKBOIN‐12: A Bayesian Optimal Interval Phase I/II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose
par: Hao Sun, et autres
Publié: (2024)

Using Off‐Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy Strategy
par: Sunita Rehal, et autres
Publié: (2026)

Confidence Intervals for Validation of Analytical Procedures Under ICH Q2 ( R2 )
par: Paul Faya, et autres
Publié: (2025)

Consistency Assessment and Regional Sample Size Calculation for MRCT Under Random Effects Model
par: Xinru Ren, et autres
Publié: (2026)

Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study
par: Andrea Callegaro, et autres
Publié: (2026)

Personalized Treatment Selection for Multivariate Ordinal Scale Outcomes and Multiple Treatments
par: Chathura Siriwardhana, et autres
Publié: (2025)

Finding the Optimal Number of Splits and Repetitions in Double Cross‐Fitting Targeted Maximum Likelihood Estimators
par: Mohammad Ehsanul Karim, et autres
Publié: (2025)

Bayesian Methods for Quality Tolerance Limit (QTL) Monitoring
par: J. C. Poythress, et autres
Publié: (2024)

Multiple Comparisons With Overdispersed Multinomial Data: Methods, Properties and Application
par: Sören Budig, et autres
Publié: (2026)

Comparative Analyses of Bioequivalence Assessment Methods for In Vitro Permeation Test Data
par: Sami Leon, et autres
Publié: (2024)

Multiplicity Adjustment Methods for a Three‐Way Crossover Bioequivalence Study
par: David Hinds, et autres
Publié: (2026)

Penalized Variable Selection for Joint AFT Random‐Effect Model With Clustered Competing‐Risks Data
par: Lin Hao, et autres
Publié: (2026)

A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality
par: Maxine Ajimi, et autres
Publié: (2026)

Comparing various Bayesian random‐effects models for pooling randomized controlled trials with rare events
par: Minghong Yao, et autres
Publié: (2024)

Statistical Consideration for Event‐Free Survival With Cure Rate in Acute Myeloid Leukemia Studies
par: Yuichiro Kaneko, et autres
Publié: (2025)

Comment on “Average Hazard as Harmonic Mean” by Chiba (2025)
par: Hajime Uno, et autres
Publié: (2025)

A Flexible Seamless Phase 2/3 Design With Biomarker‐Driven Subgroup Enrichment and Sample Size Re‐Estimation
par: Zizhong Tian, et autres
Publié: (2025)

Confidence Intervals for the Risk Difference Between Secondary and Primary Infection Based on the Method of Variance Estimates Recovery
par: Chao Chen, et autres
Publié: (2024)

Leveraging Two‐Stage δ Global Sensibility Analysis Method to Inform Parameter Estimation in PBPK Models
par: Marina Cuquerella‐Gilabert, et autres
Publié: (2026)

Predictive Biomarker Graphical Approach ( PRIME ) for Precision Medicine
par: Gina D’Angelo, et autres
Publié: (2026)

Target Aggregate Data Adjustment Method for Transportability Analysis Utilizing Summary‐Level Data From the Target Population
par: Yichen Yan, et autres
Publié: (2025)

Assessment of Responder Analyses for Patient‐Reported Outcomes With Varying Variability Between Intervention Groups: Maximum Responder Threshold and Effect
par: Joseph C. Cappelleri, et autres
Publié: (2026)

Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis
par: Heather J. Litman, et autres
Publié: (2025)

Approximate Bayesian Analysis for Borrowing External Controls for Randomized Controlled Trials With Dynamic Borrowing and Covariate Balancing Adjustment
par: Jixian Wang, et autres
Publié: (2025)

A Unified Approach to Covariate Adjustment for Survival Endpoints in Randomized Clinical Trials
par: Zhiwei Zhang, et autres
Publié: (2025)

A Weighted Geometric Average Hazard Ratio Based Sample Size Formula for Non‐Proportional Hazards and Its Application to a Smoothed Piecewise Model in Cancer Immunotherapy Trial Design
par: Qingyang Zhang, et autres
Publié: (2025)

A Tobit Partly Linear Mixed and Mixture Cure Model for the Joint Analysis of Interval‐Bounded Longitudinal Measurements and Survival Times With Cure Proportion
par: Zhanfeng Wang, et autres
Publié: (2026)

A propensity score‐integrated approach for leveraging external data in a randomized controlled trial with time‐to‐event endpoints
par: Wei‐Chen Chen, et autres
Publié: (2024)

Bayesian Hierarchical Models for Subgroup Analysis
par: Yun Wang, et autres
Publié: (2024)

Using Propensity Score Weighting to Enhance the Operating Characteristics of Power Prior in Leveraging External Data to Augment a Traditional Clinical Study
par: Heng Li, et autres
Publié: (2025)

Frailty model with change points for survival analysis
par: Masahiro Kojima, et autres
Publié: (2024)

Dynamic borrowing of historical controls adjusting for covariates in vaccine efficacy clinical trials
par: Andrea Callegaro, et autres
Publié: (2024)

Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance
par: Jonathan M. Siegel, et autres
Publié: (2024)

Simulation‐based sample size calculations of marginal proportional means models for recurrent events with competing risks
par: Julie Funch Furberg, et autres
Publié: (2024)

Predictive Ppk calculations for biologics and vaccines using a Bayesian approach – a tutorial
par: Jos Weusten, et autres
Publié: (2024)

Principles for Defining Estimands in Clinical Trials—A Proposal
par: Tobias Mütze, et autres
Publié: (2024)

Quality by Design for Preclinical In Vitro Assay Development
par: Jonathan Jones, et autres
Publié: (2024)